ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Daiichi Sankyo-AstraZeneca’s ENHERTU gets FDA priority review
Share this article A decision on the approval of ENHERTU to treat unresectable or metastatic HER2-positive solid tumours is expected on 30 May 2024. Credit: